Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 1500
- Registration Number
- NCT05919511
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 186
- Registration Number
- NCT05906628
- Locations
- 🇺🇸
First Oc Dermatology, Fountain Valley, California, United States
🇺🇸Skin Research of South Florida, Llc, Miami, Florida, United States
🇺🇸Dermatology Clinical Research Center of San Antonio, San Antonio, Texas, United States
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 8
- Registration Number
- NCT05909995
- Locations
- 🇿🇦
Johese Clinical Research: Midstream, Centurion, South Africa
🇨🇦Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇿🇦Mary Potter Oncology Centre, Pretoria, South Africa
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 63
- Registration Number
- NCT05888844
- Locations
- 🇫🇷
Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume, Rouen Cedex, France
🇫🇷Centre Hospitalier de Pau - Hôpital François Mitterrand, Pau Cedex, France
🇫🇷University Hospital of Saint Etienne, Saint Etienne Cedex 2, France
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 73
- Registration Number
- NCT05879822
- Locations
- 🇧🇷
Fundacao Pio Xii Hospital de Cancer de Barretos, Barretos, Brazil
🇧🇷Cionc-Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil
🇧🇷Oncosite - Centro de Pesquisa Clinica E Oncologia, Ijui, Brazil
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
- Conditions
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 240
- Registration Number
- NCT05851443
- Locations
- 🇦🇷
Centro Medico Respire, San Fernando, Argentina
🇺🇸Allervie Clinical Research, Birmingham, Alabama, United States
🇺🇸Kern Allergy Medical Clinic, Inc, Bakersfield, California, United States
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 245
- Registration Number
- NCT05836324
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷Institut Gustave Roussy, Villejuif Cedex, France
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 180
- Registration Number
- NCT05764161
- Locations
- 🇺🇸
Northwest Arkansas Clinical Trials Center, Arkansas, Arkansas, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Clinical Science Institute Clinical Research Specialists Inc, Santa Monica, California, United States
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
- Conditions
- Interventions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 204
- Registration Number
- NCT05755438
- Locations
- 🇩🇪
Universitaetsklinikum Carl Gustav Carus Tu Dresden, Dresden, Germany
🇩🇪Universitatsklinikum Schleswig Holstein, Kiel, Germany
🇩🇪Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii, Mainz, Germany
A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo
- Conditions
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 49
- Registration Number
- NCT05750823
- Locations
- 🇺🇸
Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California, United States
🇨🇦Research Toronto, Toronto, Ontario, Canada
🇺🇸Center For Dermatology Clinical Research, Inc, Fremont, California, United States